Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 64 peer-reviewed journal articles Updated
Neurology · IRF2BPL-Related Neurodevelopmental Disorder

IRF2BPL-Related Neurodevelopmental Disorder (NEDAMSS): A Patient Guide

At a Glance

NEDAMSS is an ultra-rare IRF2BPL-related genetic disorder that can cause developmental regression, abnormal movements, speech loss, and seizures. Genetic testing is central to diagnosis, while coordinated care focuses on seizure control, communication, feeding, mobility, and comfort.

IRF2BPL-related neurodevelopmental disorder, commonly known as NEDAMSS (neurodevelopmental disorder with regression, abnormal movements, loss of speech, and seizures), is an ultra-rare genetic condition that primarily affects the brain and nervous system [1]. For many families, the journey toward a diagnosis begins after a period of what is often reported to be typical or near-typical early development. This initial progress is sometimes followed by a period of neurological regression, where a child begins to lose previously acquired skills, such as the ability to speak, walk, or coordinate movements [2][3]. This shift can be a profound shock, as the condition changes from a developmental delay into a more complex neurological challenge [1].

The core features of NEDAMSS often involve a combination of movement disorders and epilepsy, though it is important to note that not every child will develop every feature. Children may develop dystonia (involuntary muscle twisting), ataxia (balance and coordination issues), or spasticity (muscle stiffness), which can make daily activities like sitting or eating more difficult [4][5]. Seizures are also a hallmark of the syndrome and can vary significantly from one child to another, ranging from infantile spasms in very young children to drug-resistant epilepsy that requires specialized management [6][7]. Because the symptoms and the timing of regression vary widely—with some individuals showing signs in infancy and others retaining speech or not showing signs until adolescence—each child’s experience with the disorder is highly individualized [8][5].

The condition is caused by changes, or variants, in the IRF2BPL gene, which normally helps regulate how other genes function in the brain [9]. Most of these variants are de novo, meaning they occur spontaneously and are not inherited from a parent [1]. NEDAMSS is diagnosed through advanced genetic testing, such as a multigene panel or Whole Exome Sequencing (WES), which uses a blood or saliva sample to identify the specific change in the DNA [3][10]. While other tests like MRI or EEG are important for monitoring brain health, they are often non-specific and are used alongside clinical assessment to rule out other conditions rather than to provide a definitive diagnosis on their own [1][11].

While there is currently no cure for NEDAMSS, the standard of care focuses on high-quality, multidisciplinary support to manage symptoms and improve quality of life [8]. This approach involves a team of specialists—including neurologists, physical and occupational therapists, and speech-language pathologists—who work together to manage seizures, support communication through augmentative technology, and ensure safe feeding [12][13]. Preclinical research into potential future treatments is ongoing in laboratories, but the primary goal today is to provide a supportive environment that maximizes each child’s comfort, mobility, and ability to engage with their family and the world around them [14][15].

In this guide

6 chapters

01

Understanding Your Child's NEDAMSS Diagnosis

Learn what a NEDAMSS diagnosis means for your child, including IRF2BPL genetics, regression, seizures, movement changes, supportive care, and genetic counseling.

02

Symptoms and Disease Progression in NEDAMSS

Learn how NEDAMSS may progress from developmental regression to speech loss, seizures, dystonia, ataxia, swallowing problems, and variable symptoms over time.

03

Genetics, Diagnostics, and Mimics of NEDAMSS

Learn how NEDAMSS is diagnosed through IRF2BPL testing, trio sequencing, VUS review, and evaluation for Rett syndrome, Batten disease, and other mimics.

04

Managing Seizures and Neurological Emergencies

Learn how caregivers can recognize NEDAMSS seizure, dystonia, breathing, swallowing, and responsiveness emergencies, use rescue plans, and know when to seek help.

05

Daily Management of Movement, Speech, and Feeding

Learn how NEDAMSS affects movement, speech, and feeding, including therapy, swallowing safety, pain assessment, communication tools, and G-tube decisions.

06

Building Your Care Team and Future Research

Learn how to build a coordinated NEDAMSS care team, plan the move to adult care, evaluate preclinical research, and find verified registries and trials.

Common questions in this guide

What is NEDAMSS, and what causes it?
NEDAMSS is an ultra-rare genetic disorder that affects the brain and nervous system. It is caused by changes, called variants, in the IRF2BPL gene, and most of these changes occur spontaneously rather than being inherited from a parent.
What symptoms can children with NEDAMSS develop?
Children may lose skills they previously learned, such as speaking, walking, or coordinating movements. Involuntary muscle twisting, balance and coordination problems, muscle stiffness, and seizures can also occur, but the timing and combination of symptoms vary widely.
How is NEDAMSS diagnosed?
Diagnosis is usually based on a child's clinical features together with genetic testing, such as a multigene panel or whole exome sequencing, using blood or saliva. MRI and EEG may help monitor the brain or rule out other conditions, but they are often nonspecific and do not usually confirm NEDAMSS by themselves.
What seizure patterns can occur with NEDAMSS?
Seizures may range from infantile spasms in very young children to drug-resistant epilepsy requiring specialized management. Because seizure types and warning signs can differ, caregivers should ask the child's neurology team which changes need prompt medical attention.
Is there a cure for NEDAMSS?
There is currently no cure for NEDAMSS. Care focuses on managing seizures and movement symptoms, supporting communication and feeding, and improving comfort, mobility, safety, and quality of life through a coordinated team.
Which specialists may be involved in a child's NEDAMSS care?
Care may involve a neurologist, epileptologist, and movement-disorder specialist, along with physical and occupational therapists and a speech-language pathologist. A feeding clinic and communication supports, including augmentative technology, may also be helpful.
Can NEDAMSS be inherited by other children in the family?
Most IRF2BPL variants linked with NEDAMSS occur de novo, meaning they arise spontaneously and are not inherited from a parent. The chance of recurrence depends on the specific genetic finding and family circumstances, so families should discuss the result with their medical team.

Get notified when new evidence is published on IRF2BPL-related regressive neurodevelopmental disorder-dystonia-seizures syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (15)
  1. 1

    De novo truncating variants in the intronless IRF2BPL are responsible for developmental epileptic encephalopathy.

    Tran Mau-Them F, Guibaud L, Duplomb L, et al.

    Genetics in medicine : official journal of the American College of Medical Genetics 2019; (21(4)):1008-1014 doi:10.1038/s41436-018-0143-0.

    PMID: 30166628
  2. 2

    Patient and Family Reported Clinical Picture of IRF2BPL-Related Disorders.

    Goldstone-Joubert Z, Pascual DM, Bailey LA, et al.

    American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics 2026; doi:10.1002/ajmg.b.70032.

    PMID: 42629971
  3. 3

    IRF2BPL-Related Disorder, Causing Neurodevelopmental Disorder with Regression, Abnormal Movements, Loss of Speech and Seizures (NEDAMSS) Is Characterized by Pathology Consistent with DRPLA.

    Venkateswaran S, Michaud J, Ito Y, et al.

    Movement disorders : official journal of the Movement Disorder Society 2024; (39(11)):2102-2109 doi:10.1002/mds.29938.

    PMID: 39224955
  4. 4

    Genetic analysis of IRF2BPL in a Taiwanese dystonia cohort: The genotype and phenotype correlation.

    Chen PS, Chen YF, Chiu JY, et al.

    Annals of clinical and translational neurology 2024; (11(6)):1557-1566 doi:10.1002/acn3.52072.

    PMID: 38650104
  5. 5

    IRF2BPL as a novel causative gene for progressive myoclonus epilepsy.

    Gardella E, Michelucci R, Christensen HM, et al.

    Epilepsia 2023; (64(8)):e170-e176 doi:10.1111/epi.17634.

    PMID: 37114479
  6. 6

    Recurrent IRF2BPL c.2152del Variant in NEDAMSS: A Case Report and Comparative Analysis.

    von Quednow E, Bragado López S, Martínez González M, Carrascosa-Romero MC

    American journal of medical genetics. Part A 2026; (200(7)):1702-1709 doi:10.1002/ajmg.a.70113.

    PMID: 41813602
  7. 7

    IRF2BPL gene mutation: Expanding on neurologic phenotypes.

    Shelkowitz E, Singh JK, Larson A, Elias ER

    American journal of medical genetics. Part A 2019; (179(11)):2263-2271 doi:10.1002/ajmg.a.61328.

    PMID: 31432588
  8. 8

    Novel human neurodevelopmental and neurodegenerative disease associated with IRF2BPL gene variants-mechanisms and therapeutic avenues.

    Bauersachs D, Bomholtz L, Del Rey Mateos S, et al.

    Frontiers in neuroscience 2024; (18()):1426177 doi:10.3389/fnins.2024.1426177.

    PMID: 38903604
  9. 9

    NEDAMSS syndrome-related truncating and missense mutations are associated with aberrant liquid-liquid phase separation of IRF2BPL.

    Dell'Oca M, Boggio Bozzo S, Vaglietti S, et al.

    Nature communications 2026; (17(1)).

    PMID: 41760624
  10. 10

    Diagnostic yield of 1000 trio analyses with exome and genome sequencing in a clinical setting.

    Malmgren H, Kvarnung M, Gustafsson P, et al.

    Frontiers in genetics 2025; (16()):1580879 doi:10.3389/fgene.2025.1580879.

    PMID: 40620702
  11. 11

    Neurodevelopmental disorder caused by a truncating de novo variant of IRF2BPL.

    Qian XH, Liu XY, Zhu ZY, et al.

    Seizure 2021; (84()):47-52 doi:10.1016/j.seizure.2020.11.006.

    PMID: 33278788
  12. 12

    Digital technology interventions for communication skills in persons with neurodevelopmental disorders: a scoping review.

    Zorzi S, Lubkina V, Jēkabsone I, Berteotti L

    Research in developmental disabilities 2025; (164()):105080 doi:10.1016/j.ridd.2025.105080.

    PMID: 40737720
  13. 13

    European Society for Paediatric Gastroenterology, Hepatology and Nutrition Guidelines for the Evaluation and Treatment of Gastrointestinal and Nutritional Complications in Children With Neurological Impairment.

    Romano C, van Wynckel M, Hulst J, et al.

    Journal of pediatric gastroenterology and nutrition 2017; (65(2)):242-264 doi:10.1097/MPG.0000000000001646.

    PMID: 28737572
  14. 14

    Mechanisms of IRF2BPL-related disorders and identification of a potential therapeutic strategy.

    Sinha Ray S, Dutta D, Dennys C, et al.

    Cell reports 2022; (41(10)):111751 doi:10.1016/j.celrep.2022.111751.

    PMID: 36476864
  15. 15

    Clinical characterization of IRF2BPL mutation: Case series and review of the literature.

    Lou X, Li W, Pang M, et al.

    Medicine 2025; (104(1)):e41078 doi:10.1097/MD.0000000000041078.

    PMID: 40184118

This page is for informational purposes only and does not constitute medical advice. Your child's neurologist and multidisciplinary care team can interpret genetic results and recommend individualized care.